Is Arbutus Biopharma Corporation (ABUS) Overvalued?
We dive into why Arbutus Biopharma Corporation (ABUS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Michael Rose
Stock Evaluator: Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation ABUS
$4.98
0.14
2.89%
August 19, 2026 4:00:00 PM
EST
Volume: 3,427,972
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Commentary & Analysis
Why Arbutus Biopharma Corporation’s (ABUS) Stock Is Down 5.54%
As of Friday, July 10, Arbutus Biopharma Corporation’s ABUS share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Arbutus Biopharma Corporation’s (ABUS) Stock Is Down 5.13%
As of Tuesday, June 02, Arbutus Biopharma Corporation’s ABUS share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
What You Need to Know About Arbutus Biopharma Corporation's Q2 Earnings
Arbutus Biopharma Corporation's fiscal Q2 earnings report was released on Wednesday, May 13. Let's dive in to see if (ABUS) missed or beat analyst's expectations.Michael Rose
Why Arbutus Biopharma Corporation’s (ABUS) Stock Is Up 5.06%
As of Wednesday, April 15, Arbutus Biopharma Corporation’s ABUS share price has surged by 5.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ABUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $985.3 | $289.8 | 45% |
|
| Shares Out (Mil) | 197.5 | 54.4 | 76% |
|
| Institutional Ownership | 98.6% | 92.8% | 80% |
|
| Float (Mil) | 122.7 | 39.7 | 65% |
|
| Beta | 0.60 | 0.93 | 35% |
|
| Avg Daily Volume (000s) | 1,452 | 524 | 76% |
|
| Price Change (52-week) |
47.3% | 60.8% | 78% |
|
| Growth | ABUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.4% | 13.6% | 74% |
|
| Net Income (5yr) | 12.1% | (10.1%) | 58% |
|
| EPS (5yr) | 29.4% | 16.0% | 80 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.8%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.020) | $0.743 | ($0.080) | |
| Month Ago EPS | ($0.040) | ($0.158) | na | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.040) | ($0.164) | na | |
| Year/Year Chg | (33.3%) | (524.6%) | na | |
| Financials | ABUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $182 | $37 | 31% |
|
| Net Income (TTM) (Mil) | $153 | ($43) | 65% |
|
| EPS (TTM) | $0.790 | ($1.400) | 58% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($18) | $2 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $819 | $208 | 38% |
|
| Valuation | ABUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.80 | 2.86 | 71% |
|
| P/E | 6.3 | 19.1 | 7% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.0 | 9% |
|
| Ratios | ABUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 90.2% | 64.7% | 93% |
|
| Net Margin | 84.2% | (75.9%) | 99% |
|
| ROA | 81.1% | (47.6%) | 100% |
|
| ROE | 89.6% | (54.1%) | 96% |
|
| Liabilities to Assets | 5.6% | 30.2% | 3% |
|
| F-Score | 5 | 2 | 50% |
|
Passing Stock Screens
As of 8/19/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 6.6% |
| +/- S&P 500: | -0.9 |
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.7 |
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
